Senolytic treatment with dasatinib and quercetin does not improve overall influenza responses in aged mice.

ABSTRACT: Age is the greatest risk factor for adverse outcomes following influenza (flu) infection. The increased burden of senescent cells with age has been identified as a root cause in many diseases of aging and targeting these cells with drugs termed senolytics has shown promise in alleviating many age-related declines across organ systems. However, there is little known whether targeting these cells will improve age-related deficits in the immune system. Here, we utilized a well characterized senolytic treatment with a combination of dasatinib and quercetin (D + Q) to clear aged (18-20 months) mice of senescent cells prior to a flu infection. We comprehensively profiled immune responses during the primary infection as well as development of immune memory and protection following pathogen reenco

SUBMITTER: Torrance BL 

PROVIDER: S-EPMC10313122 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature